Targeting mTORC2 in lung squamous cell carcinoma improves anti-tumor immunity
Targeting mTORC2 in lung squamous cell carcinoma improves anti-tumor immunity through the PSGL-1-VISTA axis Summary Targeting mTORC2 in lung squamous cell carcinoma (LUSC) enhances anti-tumor immunity by modulating the PSGL-1-VISTA pathway. Specifically, mTORC2 Read More